A potential role for nilotinib in KIT-mutated melanoma

Bibliography

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010, CA. Cancer J Clin 2010;60(5):277
   PubMed Web of Science ®Google Scholar
• World Health Organization. Skin cancers. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html [Accessed 4 June 2010]
   Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ, Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004;22:1118-25
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-5701
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grab JJ, Aaronson N, Randomized Phase III study of Temozolomide Versus Dacarbazine in the Treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
   PubMed Web of Science ®Google Scholar
• Parkinson DR, Abrams JS, Wiernik PH, Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8:1650-6
   PubMed Web of Science ®Google Scholar
• Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am J Clin Dermatol 2003;4:333-46
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl Med. 2010;363:711-23
   Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Fecher LA, Cummings SD, Keefe MJ, Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-20
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated BRAF in metastatic Melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Ribas A, Kim KB, Schuchter LM. BRIM-2: an open -label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29(Suppl):abstract 8509
   Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Mechanisms of disease: tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Busam KJ, Francone TD, L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-64
   PubMed Web of Science ®Google Scholar
• Went PT, Dirnhofer S, Bundi M, Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-22
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Layfield LJ, Holden JA. c-KIT mutation analysis for diagnosis of gastrointestinal stromal tumors in fine needle aspiration specimens. Cancer 2005;105:165-70
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-Kit-activating mutations by high-resolution amplicon melting curve analysis. Hum Pathol 2005;36:486-93
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL, Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V, Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11
   PubMed Web of Science ®Google Scholar
• Eton O, Billings L, Kim K, Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 2004;22(717s Suppl):abstract 7528
   Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A, Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, KIT as a Therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol 2011;29:2904-9
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu PY, Lee SJ, Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
   PubMed Web of Science ®Google Scholar
• Woodman SE, Trent JC, Lazar SHA, Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P). J Clin Oncol 2009;27(15s Suppl):abstract 9019
   Google Scholar
• Kluger HM, Dudek AZ, McCann C, A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011;117:2202-8
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Lee SJ, Lawrence DP, A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: an Eastern Cooperative Oncology Group study (E2607). Journal of Clinical Oncology 2010;28(15s Suppl):TPS312
   Google Scholar
• Cho JH, Kim KM, Kwon M, Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2011; Published online: 09 November 2011
   PubMed Web of Science ®Google Scholar
• Sawaki A, Nishida T, Doi T, Phase 2 Study of Nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633-41
   PubMed Web of Science ®Google Scholar
• Jarkowski A, Sweeney RP. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy 2008;28(11):1374-82
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib(formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Manley PW, Bruggen J, Fabbro D, Extended kinase profiling of the Bcr-Abl inhibitor nilotinib [abstract]. Proc Am Assoc Cancer Res 2007;48:abstract 3249
   Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib (Formerly AMN107), a Highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110(10):3540-6
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362(24):2251-9
   PubMed Web of Science ®Google Scholar
• Prenen H, Guetens G, De Boeck G, Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006;77:11-16
   PubMed Web of Science ®Google Scholar
• Tanaka C, Yin OQP, Sethuraman V, Tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010;87:197-203
   PubMed Web of Science ®Google Scholar
• Cullinane C, Natoli A, Hui Y, Imatinib-Resistant KIT-driven tumor model preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther 2010;9:1461-8
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51
   PubMed Web of Science ®Google Scholar
• Available from: http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=242067
   Google Scholar
• Antonescu CR, Besmer P, Guo T, Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res 2005;11(11):4182-90
   PubMed Web of Science ®Google Scholar
• Sapi Z, Fule T, Hajdu M, The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol 2011;20(1):22-33
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Astolfi A, Nannini M, The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med 2010;8:117
   PubMedGoogle Scholar
• Muhlenberg T, Zhang Y, Wagner AJ, Inhibitors of Deacetylases suppress oncogenic KIT gastrointestinal stromal tumors signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 2009;69:6941-50
   PubMed Web of Science ®Google Scholar